Free Trial
OTCMKTS:BVNRY

Bavarian Nordic (BVNRY) Stock Price, News & Analysis

Bavarian Nordic logo
$11.78 +0.30 (+2.61%)
As of 10/9/2026 03:57 PM Eastern

About Bavarian Nordic Stock (OTCMKTS:BVNRY)

Advanced

Key Stats

Today's Range
$11.72
▼
$11.80
50-Day Range
$9.03
▼
$11.78
52-Week Range
$8.67
▼
$13.00
Volume
10,160 shs
Average Volume
4,082 shs
Market Capitalization
$2.80 billion
P/E Ratio
11.90
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bavarian Nordic A/S is a Denmark-based biotechnology company focused on developing, manufacturing and commercializing vaccines. The company serves government agencies, healthcare providers, travelers and other customers through a portfolio of products addressing infectious diseases and public-health preparedness.

Its best-known vaccine is MVA-BN, marketed as Jynneos in the United States and Imvanex in the European Union, for protection against smallpox and mpox. Bavarian Nordic also markets vaccines for rabies, including Rabipur and RabAvert, and for tick-borne encephalitis under the Encepur brand. Its portfolio has also included travel vaccines such as Vaxchora for cholera.

Founded in 1994 and headquartered in Copenhagen, Bavarian Nordic has developed a global commercial and supply network, with products distributed in North America, Europe and other international markets. The company also works with governments and public-health organizations on vaccine supply and preparedness programs. Paul Chaplin has served as the company’s president and chief executive officer.

AI Generated. May Contain Errors.

Receive BVNRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bavarian Nordic and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BVNRY Stock News Headlines

The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
Bavarian Nordic AS ADR BVNRY
Bavarian Nordic A/S
See More Headlines

BVNRY Stock Analysis - Frequently Asked Questions

Bavarian Nordic's stock was trading at $9.9260 at the start of the year. Since then, BVNRY stock has increased by 18.7% and is now trading at $11.78.

Bavarian Nordic (OTCMKTS:BVNRY) announced its quarterly earnings data on Friday, August, 21st. The company reported $0.46 earnings per share (EPS) for the quarter. The business had revenue of $316.47 million for the quarter. Bavarian Nordic had a net margin of 24.36% and a trailing twelve-month return on equity of 11.97%.

Shares of BVNRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/21/2026
Today
10/11/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:BVNRY
CIK
N/A
Employees
1,692
Year Founded
1994

Profitability

EPS (Trailing Twelve Months)
$0.99
Trailing P/E Ratio
11.90
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$208.23 million
Net Margins
24.36%
Pretax Margin
30.86%
Return on Equity
11.97%
Return on Assets
10.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.53
Quick Ratio
3.91

Sales & Book Value

Annual Sales
$945.43 million
Price / Sales
2.96
Cash Flow
$1.35 per share
Price / Cash Flow
8.75
Book Value
$8.20 per share
Price / Book
1.44

Miscellaneous

Outstanding Shares
237,800,000
Free Float
N/A
Market Cap
$2.80 billion
Optionable
Not Optionable
Beta
1.25

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (OTCMKTS:BVNRY) was last updated on 10/9/2026 by MarketBeat.com Staff.
From Our Partners